Rothrock S G, Green S M, Harper M B, Clark M C, McIlmail D P, Bachur R
Department of Emergency Medicine, Orlando Regional Medical Center, FL 32806, USA.
Acad Emerg Med. 1998 Jun;5(6):599-606. doi: 10.1111/j.1553-2712.1998.tb02468.x.
To determine whether parenteral antibiotics are superior to oral antibiotics in preventing serious bacterial infections in children with Streptococcus pneumoniae occult bacteremia.
Using the MEDLINE database, the English language literature was searched for all publications concerning bacteremia, fever, or Streptococcus pneumoniae from 1966 to January 1, 1997. All nonduplicative studies with a series of children with S. pneumoniae occult bacteremia having both orally treated and parenterally treated groups were reviewed. Children were excluded from individual studies if at the time of their initial evaluation they were immunocompromised, had a serious bacterial infection, underwent a lumbar puncture, or did not receive antibiotics.
Only 4 studies met study criteria. From these studies, 511 total cases of S. pneumoniae occult bacteremia were identified. Ten of 290 (3.4%) in the oral group and 5 of 221 (2.3%) in the parenteral antibiotic group developed serious bacterial infections (pooled p-value = 0.467, pooled OR = 1.48; 95% CI, 0.5-4.3). Two patients in the oral group (0.7%) and 2 patients in the parenteral group (0.9%) developed meningitis (pooled p-value = 0.699, pooled OR = 0.67; 95% CI, 0.1-5.1).
The rates of serious bacterial infections and meningitis did not differ between children who were treated with oral and parenteral antibiotics. The extremely low rate of complications observed in both groups suggests no clinically significant difference between therapies. A study with >7,500 bacteremic children (or >300,000 febrile children) would be needed to have 80% power to prove parenteral antibiotics are superior to oral antibiotics in preventing serious bacterial infections.
确定在预防肺炎链球菌隐性菌血症患儿发生严重细菌感染方面,胃肠外抗生素是否优于口服抗生素。
利用MEDLINE数据库,检索1966年至1997年1月1日期间所有关于菌血症、发热或肺炎链球菌的英文文献。对所有涉及肺炎链球菌隐性菌血症患儿系列且有口服治疗组和胃肠外治疗组的非重复研究进行综述。如果儿童在初始评估时存在免疫功能低下、患有严重细菌感染、接受过腰椎穿刺或未接受抗生素治疗,则将其排除在个别研究之外。
仅有4项研究符合研究标准。从这些研究中,共确定了511例肺炎链球菌隐性菌血症病例。口服组290例中有10例(3.4%)发生严重细菌感染,胃肠外抗生素组221例中有5例(2.3%)发生严重细菌感染(合并p值 = 0.467,合并OR = 1.48;95%可信区间,0.5 - 4.3)。口服组2例患者(0.7%)和胃肠外治疗组2例患者(0.9%)发生脑膜炎(合并p值 = 0.699,合并OR = 0.67;95%可信区间,0.1 - 5.1)。
口服和胃肠外抗生素治疗的儿童发生严重细菌感染和脑膜炎的发生率无差异。两组观察到的极低并发症发生率表明两种治疗方法在临床上无显著差异。需要一项纳入超过7500例菌血症患儿(或超过300000例发热患儿)的研究,才有80%的把握证明胃肠外抗生素在预防严重细菌感染方面优于口服抗生素。